Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
Close-up of human immune cells on a glass slide in a laboratory setting.

May 8, 2026

AstraZeneca Expands AI Biotech Partnership With Immunai Through 2027

AstraZeneca has strengthened its partnership with Immunai, focusing on AI-driven advancements in oncology and beyond. This collaboration, now extended through 2027, underscores the pharmaceutical giant's commitment to integrating cutting-edge technology into its drug development processes.The latest agreement allows Immunai to potentially earn up to $37.5 million as AstraZeneca leverages Immunai’s AMICA-OS platform, which utilizes AI to model the human immune system through extensive clinical da
Model of the human immune system in a research lab

May 7, 2026

AstraZeneca expands AI partnership with Immunai in deal worth up to $37.5 million

AstraZeneca is enhancing its collaboration with Immunai, focusing on artificial intelligence for oncology drug development. The expanded partnership could yield up to $37.5 million for Immunai through 2027, underscoring the increasing significance of AI technologies in pharmaceutical research.This collaboration builds on an existing relationship that began in 2024, with AstraZeneca utilizing Immunai's AMICA-OS platform. This AI-driven system models the human immune system, leveraging one of the
A minimalist illustration of a financial report with a rising chart

May 6, 2026

RVTY Q1 2026 Deep Dive: Portfolio Pruning and AI Investments Shape Outlook

Revvity's Q1 2026 results reveal a mixed performance with a focus on strategic adjustments and AI investments.Revvity (NYSE:RVTY) reported a 9.3% year-on-year revenue increase, totaling $686.9 million for Q1 CY2026, but fell short of market expectations, which were set at $705.1 million. Despite this, the company exceeded adjusted earnings per share (EPS) estimates, delivering $1.06 compared to the expected $1.01. The firm also adjusted its full-year revenue guidance downward to $2.83 billion fr
A minimalist illustration of a pill and a molecule in a dark palette.

May 6, 2026

AI in Drug Development: Where Value is Emerging

The integration of AI into drug development is reshaping the pharmaceutical landscape, promising faster and more cost-effective processes.The pharmaceutical sector is characterized by lengthy development timelines, substantial financial commitments, and high failure rates. AI emerges as a potential game-changer, aiming to streamline drug discovery and enhance success rates. However, the diverse nature of AI technologies and the extended timelines required for drug development make it challenging
A minimalist illustration of a test tube with bubbles, symbolizing drug discovery.

May 4, 2026

Big Tech Targets Drug Discovery with Wave of Life Science Platforms

Big tech companies are increasingly focusing on drug discovery, leveraging advanced AI and cloud platforms to streamline research and development processes.Nvidia's CEO, Jensen Huang, emphasizes that the future of accelerated computing lies in application acceleration rather than just hardware. This is particularly relevant in drug discovery, where lengthy approval processes and high clinical trial failure rates present significant challenges. To address these issues, major players like Amazon W
Silhouette of a human tonsil organoid

May 2, 2026

ALP Bio Raises €1.9M to Advance Immune Organoid AI Platform

ALP Bio AG has successfully raised €1.9 million in pre-seed funding to enhance its innovative immune organoid AI platform aimed at addressing immunogenicity risks in drug development.The funding round, led by Munich-based 42CAP with contributions from Venture Kick and angel investors, marks a significant step for the Swiss biotech startup founded in 2025. ALP Bio's platform uniquely integrates human tonsil organoid biology with generative AI to identify and mitigate the formation of anti-drug an
A minimalist representation of a drug compound in a dark palette.

May 2, 2026

OpenAI GPT-Rosalind: Specialized Life Sciences AI for Faster Drug Discovery Research

OpenAI has introduced GPT-Rosalind, a specialized AI model aimed at enhancing drug discovery efforts in the life sciences sector. This advanced tool is designed to assist researchers by leveraging deep scientific reasoning to navigate the complexities of biology and drug development, particularly within regulated environments.GPT-Rosalind operates under a controlled research preview, limiting access to qualified scientific users in regulated laboratory settings. Its primary focus is on translati
A minimalist illustration of a pill symbolizing drug discovery.

May 1, 2026

AI Tools Life Sciences Companies Are Using

Artificial Intelligence (AI) is increasingly embedded in the life sciences sector, influencing various stages from drug discovery to clinical research and manufacturing.The integration of AI tools in life sciences is transforming operations across the pharmaceutical value chain. Approximately 80% of professionals in this field utilize AI in drug discovery, with a significant majority of executives anticipating that intelligent automation will greatly impact the industry in the coming years. Comp
A minimalist representation of a small molecule in flat design.

Apr 29, 2026

Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Glob

Lantern Pharma has transformed its predictBBB.ai platform into a Large Quantitative Model (LQM), enhancing its capabilities for precision molecular intelligence in drug development. This new real-time engine is now accessible globally through a web interface, allowing researchers to obtain comprehensive analyses of small molecules with unprecedented speed and efficiency.The evolution of predictBBB.ai from a blood-brain barrier permeability predictor to a robust LQM signifies a major advancement
A flat illustration of a DNA strand and recombinase enzyme

Apr 29, 2026

Profluent & Eli Lilly Inks a Deal Worth $2.25 Bn to Develop AI-Designed Recombinases for Genetic Medicine

Profluent has partnered with Eli Lilly in a significant collaboration worth up to $2.25 billion to develop AI-designed recombinases aimed at advancing genetic medicine.This strategic alliance combines Profluent’s AI-driven protein design capabilities with Eli Lilly’s established expertise in clinical and drug development. The goal is to enhance programmable gene editing therapeutics, enabling more precise and scalable DNA editing solutions that traditional methods struggle to achieve.The partner
A minimalist illustration of a DNA helix and circuit board

Apr 28, 2026

Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point

The recent acquisition of Coefficient Bio by Anthropic for $400 million marks a significant shift in the intersection of AI and drug development, highlighting the increasing trend of collaboration between AI firms and the pharmaceutical industry.This acquisition stands out not only due to its substantial price tag but also because Coefficient Bio is a relatively nascent startup with only a handful of employees and an undisclosed technology platform. The founders bring substantial experience from
A protein model in a dimly lit lab, showcasing molecular structure.

Apr 28, 2026

Fathom Therapeutics: $47 Million Series A Raised To Advance AI And Physics-Based Drug Design Platform

Fathom Therapeutics has successfully secured $47 million in a Series A funding round to enhance its innovative drug discovery platform that leverages artificial intelligence and physics.This financing round, led by Sutter Hill Ventures and supported by notable investors like Chemistry and Alexandria Venture Investments, aims to propel the development of Fathom's AI-powered platform, Microcosmos. This proprietary engine simulates protein dynamics at an atomic level, offering a more accurate depic